Find link

language:

Find link is a tool written by Edward Betts.

searching for Sodium/glucose cotransporter 2 28 found (34 total)

alternate case: sodium/glucose cotransporter 2

Sodium-glucose transport proteins (965 words) [view diff] no match in snippet view article find links to article

PMID 26378978. S2CID 205098095. Research Cf (2018-12-28). "Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors". FDA. Miller D, Bihler I (1961). "The restrictions

Ipragliflozin (1,110 words) [view diff] exact match in snippet view article find links to article

17, 2014, and in Russia on May 22, 2019. Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor (gliflozin). These membrane proteins are on

Bexagliflozin (1,207 words) [view diff] no match in snippet view article find links to article

improve glycemic control in adults with type 2 diabetes. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth. The most common side

Enavogliflozin (299 words) [view diff] no match in snippet view article find links to article

"Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects". British Journal of Clinical

Sotagliflozin (1,064 words) [view diff] no match in snippet view article find links to article

used to reduce the risk of death due to heart failure. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It is taken by mouth. The most common side

Ertugliflozin (888 words) [view diff] exact match in snippet view article find links to article

infections of the female reproductive system. Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor and is in the class of drugs known as gliflozins

Canagliflozin (2,960 words) [view diff] no match in snippet view article find links to article

pregnancy and breastfeeding is not recommended. Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by increasing the amount of glucose

Velagliflozin (155 words) [view diff] no match in snippet view article find links to article

medication used for the treatment of cats. Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It is taken by mouth. Velagliflozin is indicated

Major adverse cardiovascular events (1,349 words) [view diff] no match in snippet view article find links to article

Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B (2020). "Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients

Spiroketals (528 words) [view diff] no match in snippet view article find links to article

transmission of nerve impulses Tofogliflozin is an inhibitor of human sodium glucose cotransporter 2 (hSGLT2) and was approved in 2014 in Japan for the treatment

Renal glucose reabsorption (250 words) [view diff] no match in snippet view article find links to article

Cindy; Meininger, Gary (July 2014). "Effect of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol". Journal

Dipeptidyl peptidase-4 inhibitor (1,798 words) [view diff] no match in snippet view article find links to article

Oliver N, Meeran K (April 2018). "Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl

Fournier gangrene (921 words) [view diff] no match in snippet view article find links to article

William H. (June 4, 2019). "Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases". Ann

Dapagliflozin (4,947 words) [view diff] no match in snippet view article find links to article

Gong J, et al. (2020). "Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S

Tofogliflozin (287 words) [view diff] no match in snippet view article find links to article

C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes". Journal

Anne L. Peters (1,488 words) [view diff] no match in snippet view article find links to article

Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition". Diabetes Care. Peters, AL; Henry, RR; Thakkar,

Diabetic nephropathy (5,134 words) [view diff] no match in snippet view article find links to article

load of filtered glucose, there is an up-regulation in the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubules, which cotransports sodium and

Remogliflozin etabonate (710 words) [view diff] no match in snippet view article find links to article

Khandelwal D, Sharma M (Nov 2021). "Efficacy and safety of novel sodium glucose cotransporter-2 inhibitor remogliflozin in the management of type 2 diabetes

Empagliflozin (3,736 words) [view diff] no match in snippet view article find links to article

14.6.782. PMID 18996802. Nair S, Wilding JP (January 2010). "Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus". The Journal

Efpeglenatide (516 words) [view diff] no match in snippet view article find links to article

"Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the

Erythropoietin (3,430 words) [view diff] no match in snippet view article find links to article

2010.195057. PMC 3082088. PMID 21078592. Packer M (2020). "Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy

Type 2 diabetes (12,041 words) [view diff] no match in snippet view article find links to article

(October 2022). "First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A

Diabetic ketoacidosis (5,086 words) [view diff] no match in snippet view article find links to article

Oikawa Y, Atsuda K, Shimada A (September 2021). "On-label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis

Diabetes in cats (3,807 words) [view diff] no match in snippet view article find links to article

use in the United States in December 2022. It is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor new animal drug approved by the US Food and

Diabetes medication (5,222 words) [view diff] no match in snippet view article find links to article

Drug Evaluation and Research. "Drug Safety and Availability - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors". www.fda.gov. Archived from the original

Rotavirus (9,961 words) [view diff] exact match in snippet view article find links to article

and calcium ion-dependent chloride secretion, disrupts SGLT1 (sodium/glucose cotransporter 2) transporter-mediated reabsorption of water, apparently reduces

Heart failure (15,615 words) [view diff] exact match in snippet view article find links to article

blockers, mineralocorticoid receptor antagonists (MRA), and sodium/glucose cotransporter 2 inhibitors (SGLT2 inhibitors) is the standard of care as of

COVID-19 drug development (13,124 words) [view diff] no match in snippet view article find links to article

Multiple sites in the United States September 2020 Dapagliflozin sodium-glucose cotransporter 2 inhibitor hypoglycemia agent Saint Luke's Mid America Heart